Citations

Clear

1055 citation(s) found for "Small, J C".

Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer
Skoulidis, Ferdinandos , Govindan, Ramaswamy , Vincent, Mark , Wekken, Anthonie J. van der , Aransay, N. Reguart, O’Byrne, Kenneth J. , Girard, Nicolas , Griesinger, Frank , Nishio, Makoto , Häfliger, Simon, Lindsay, Colin R. , Paulus, Astrid, Papakotoulas, Pavlos, Kim, Sang‐We , Gennatas, Spyridon , Mehta, Bhakti, Kormany, William, Sylvester, Brooke E., Ardito-Abraham, Christine , Langen, Adrianus J. de , Girard, Nicolas , Pasello, Giulia , de Langen, Adrianus Johannes , van der Wekken, Anthonie J , Govindan, Ramaswamy , Li, Bob T. , Hochmair, Maximilian Johannes , Haefliger, Simon , Reinmuth, Niels , Ferreira, Carlos Gil , Duruisseaux, M. , Dimou, Anastasios , Nduka, Chidozie U , Wang, Yang

Mayo Clinic

The Oncologist | January 23, 2025 | Volume: 30 | Issue: 1 | Pages: No page available

10.1093/oncolo/oyae356 | PMID 39846981 Get It

Abstract Introduction We describe the safety of sotorasib monotherapy in patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) and discuss practical recommendations for managing key risks. Methods Incidence rates of treatment-related adverse events (TRAEs) were pooled from 4 clinical trials: CodeBreaK 100 (NCT03600883), CodeBreaK 101 (NCT04185883), CodeBreaK 105 (NCT04380753), and CodeBreaK 200 (NCT04303780) and graded according to CTCAE v5.0. Adverse events were deemed sotorasib-related per investigator causality assessment. Results In the pooled population (n = 549), TRAEs were reported in 388 (70.7%) patients (grade 1: 124 [22.6%]; grade 2: 117 [21.3%]; grade ≥ 3: 147 [26.8%]). Gastrointestinal and hepatic TRAEs, including diarrhea (171 [31.1%]), nausea (80 [14.6%]), elevated alanine aminotransferase (ALT; 68 [12.4%]), and elevated aspartate aminotransferase (AST; 67 [12.2%]) were the most common (≥10%). Dose interruption and dose reduction of sotorasib resulted in the resolution of >90% of diarrhea events; median time to resolution were 18.0 days and 22.0 days, respectively. Similar trends were observed for elevated ALT and AST events. Patients who stopped immunotherapy <3 months before initiating sotorasib had a higher incidence of treatment-related hepatotoxicity (80/240 [33.3%]) than those who stopped immunotherapy ≥3 months before initiating sotorasib (26/188 [13.8%]). Treatment-related pneumonitis/interstitial lung disease (ILD) and corrected QT (QTc) prolongation were observed in 9 (1.6%) and 4 (0.7%) patients, respectively. Two (0.4%) patients died with TRAEs, 1 with ILD whose ultimate cause of death was disease progression, and the other with an unknown cause. Conclusions Sotorasib has a well-characterized safety profile in patients with KRAS G12C-mutated advanced NSCLC, and key risks are manageable with dose modification.
Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Mina, Syeda A. , Shanshal, Mohamed , Leventakos, Konstantinos , Parikh, Kaushal , Parikh, Kaushal

Mayo Clinic

Cancers | January 22, 2025 | Volume: 17 | Issue: 3 | Pages: 353

10.3390/cancers17030353 | PMID 39941723 Get It

Targeted therapies have changed the treatment landscape of non-small-cell lung cancer and led to improved patient survival across all stages of lung cancer. Newer advances in common and novel oncogenic drivers continue to occur at vigorous speed, making it challenging to stay up to date with the rapidly evolving field. In this article, we review the emerging perspectives in the treatment of actionable targets in lung cancer. We focus on the development of newer KRAS-directed therapies, particularly on non-G12C mutations, pan-RAS inhibitors, and RAS-GTP inhibitors. We also describe the current standard of care for EGFR- and ALK-altered NSCLC and dive into the novel treatments expected to be in the clinic soon. A similar approach is taken toward MET, HER2, RET, ROS1, and FGFR alterations as emerging targets in non-small-cell lung cancer. Finally, we conclude this review with the current body of evidence for targeting TROP-2 as a novel target, potentially of importance in post-targeted therapy scenarios.
Cerebrovascular reactivity (CVR) MRI as a biomarker for cerebral small vessel disease (SVD) related cognitive decline: Multi‐site validation in the MarkVCID Consortium
Hazel, Kaisha , Pottanat, George , Xu, Cuimei, Lucke, Emma, Gold, Brian T. , Greenberg, Steven M. , Helmer, Karl G. , Kramer, Joel H. , Mulavelil, Rachel, Singh, Herpreet , Velarde, Angel G., Kalyani, Rita R. , Rosenberg, Paul B. , Albert, Marilyn , Liu, Peiying , Lin, Zixuan , Jiang, Dengrong , Pillai, Jay J. , Bauer, Christopher E. , Jann, Kay , Jicha, Gregory A. , Maillard, Pauline , Satizábal, Claudia L. , Schwab, Kristin , Seshadri, Sudha , Wang, Danny J.J. , Moghekar, Abhay , Yaşar, Sevil , Lu, Hanzhang

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.089224 Get It

AbstractBackgroundCerebral small vessel disease (SVD) related vascular contributions represent a major factor contributing to cognitive decline and dementia (VCID) in older adults. However, there has not been a validated biomarker for the diagnosis and treatment monitoring of this condition. Recently, the US National Institute on Neurological Disorders and Stroke (NINDS) funded the MarkVCID Consortium to identify and validate clinical‐trial‐ready biomarkers for VCID. Cerebrovascular reactivity (CVR) MRI is one of the selected biomarkers that underwent multi‐site testing in the Consortium. The present study aimed to report the relationship between CVR and cognitive function at independent sites, based on a pre‐specified hypothesis.MethodCVR, the ability of cerebral small vessels to dilate upon stimulus, is thought to directly reflect physiological function of the brain microvasculature. Based on previous single‐site findings, the pre‐defined hypothesis was that CVR will be associated with the global cognitive function measured by Montreal Cognitive Assessment (MoCA) after adjusting for age, sex, and education, and this association will be observed in data collected and analyzed at each individual site.A total of 264 older participants from three sites were included (Table 1). Each site performed an identical CVR MRI procedure using 5% CO2 inhalation, and a standardized clinical and cognitive evaluation. Multi‐linear regression analysis was conducted on a site‐by‐site basis to examine the pre‐defined hypothesis.ResultGray‐matter CVR showed a positive association with MoCA score after adjustment for age, sex, and education, in which participants with higher CVR had higher MoCA scores. This relationship was reproduced at each site (Figure 1, p<0.05 for each), confirming our pre‐specified hypothesis.In the secondary analysis of all data together, higher gray‐matter CVR was found to be significantly associated with better executive function measure of item response theory (IRT) score (β=2.87, p=0.003).ConclusionThe present study evaluated the relationship between CVR and cognition in a multi‐center setting. CVR was found to be positively associated with global cognitive function measured by the MoCA, which was shown to be reproducible across different sites with diverse cohorts. These findings support the utility of CVR as a biomarker in future clinical trials of SVD and VCID.
Small-Bowel Metastatic Melanoma From Primary Mucosal Melanoma of the Anus: A Comprehensive Case Report
Pons, A, Lukens, Frank , Gomez Pons, Andrea, Lukens, Frank J., Pons, Andrea Gomez, Osagiede, Osayande

Mayo Clinic

ACG Case Reports Journal | December 27, 2024 | Volume: 12 | Issue: 1 | Pages: e01577

10.14309/crj.0000000000001577 | PMID 39734392 Get It

ABSTRACT Anorectal mucosal melanoma (ARMM) is exceptionally rare, highly malignant, and characterized by a poor prognosis. We present the case of a 76-year-old woman with ARMM and recurrent gastrointestinal (GI) bleeding/anemia caused by small-bowel metastases, which was successfully managed with laparoscopic resection. ARMM is an aggressive type of cancer that has the potential to metastasize to the GI tract approximately 4.5 years after the primary diagnosis. Intussusception and GI bleed are potential complications. Small-bowel metastatic melanoma typically goes undiagnosed until autopsy and requires a multidisciplinary approach. Key treatment options include surgery and immunotherapy to improve patient outcomes.
EXACT-Net: Framework for EHR-Guided Lung Tumor Auto-Segmentation for Non-Small Cell Lung Cancer Radiotherapy
Kelly, Katelyn, Feng, Xue , Luo, Yi , Zhang, Rui , Xu, Ziyue , Chen, Quan , Ding, Kai , Chen, Quan , Huang, Gaofeng , Feng, Xue , Xu, Ziyue , Ding, Kai , Hooshangnejad, Hamed , Huang, Gaofeng , Kelly, Katelyn

Mayo Clinic

Cancers | December 9, 2024 | Volume: 16 | Issue: 23 | Pages: 4097

10.3390/cancers16234097 | PMID 39682283 Get It

Background/Objectives: Lung cancer is a devastating disease with the highest mortality rate among cancer types. Over 60% of non-small cell lung cancer (NSCLC) patients, accounting for 87% of lung cancer diagnoses, require radiation therapy. Rapid treatment initiation significantly increases the patient’s survival rate and reduces the mortality rate. Accurate tumor segmentation is a critical step in diagnosing and treating NSCLC. Manual segmentation is time- and labor-consuming and causes delays in treatment initiation. Although many lung nodule detection methods, including deep learning-based models, have been proposed. Most of these methods still have a long-standing problem of high false positives (FPs). Methods: Here, we developed an electronic health record (EHR)-guided lung tumor auto-segmentation called EXACT-Net (EHR-enhanced eXACtitude in Tumor segmentation), where the extracted information from EHRs using a pre-trained large language model (LLM) was used to remove the FPs and keep the TP nodules only. Results: The auto-segmentation model was trained on NSCLC patients’ computed tomography (CT), and the pre-trained LLM was used with the zero-shot learning approach. Our approach resulted in a 250% boost in successful nodule detection using the data from ten NSCLC patients treated in our institution. Conclusions: We demonstrated that combining vision-language information in EXACT-Net multi-modal AI framework greatly enhances the performance of vision only models, paving the road to multimodal AI framework for medical image processing.
Curative immunotherapy-based strategies for non-metastatic non-small cell lung cancer
Kuhlman, Justin J. , Li, Shenduo , Manochakian, Rami , Lou, Yanyan , Zhao, Yujie , Manochakian, Rami , Kuhlman, Justin

Mayo Clinic

Exploration of Targeted Anti-tumor Therapy | December 6, 2024 | Volume: 5 | Issue: 6 | Pages: 1373-1392

10.37349/etat.2024.00281 | PMID 39764421 Get It

The emergence of immunotherapy has ushered in a new era in the management of non-small cell lung cancer (NSCLC). Various immune check point inhibitors have demonstrated significant benefit in the management of locally advanced NSCLC that are treated with either surgery or concurrent chemoradiation. We provide a comprehensive and up-to-date review of data from key studies, discuss the challenging clinical issue regarding the timing and duration of immunotherapy in patients undergoing surgery, and highlight the unmet needs and future directions of immunotherapy in NSCLC.
Efficacy of Small Molecule Kinase Inhibitors in Histiocytic Neoplasms with Non-BRAFV600E Mutations: Concordance of Pre-Clinical Predictions to Clinical Responses
Rodriguez-Rosario, Alanis Enid, Medina, Aldo Adrian Acosta, Ruan, Gordon , Zanwar, Saurabh , Abeykoon, Jithma P. , Bennani, N. Nora , Goyal, Gaurav , Ravindran, Aishwarya , Rech, Karen L. , Shah, Meera , Yi, Dongni , Go, Ronald S.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4564-4564

10.1182/blood-2024-205474 Get It

Introduction. Erdheim-Chester disease (ECD), Langerhans cell histiocytosis (LCH) and Rosai-Dorfman disease (RDD) belong to a group of histiocytic neoplasms often driven by mutations in the mitogen activated protein kinase (MAPK) pathway, most commonly in BRAF, MAP2K1 and K/NRAS. Currently, there are 2 drugs approved by the US Food and Drug Administration for the treatment of histiocytic neoplasms, cobimetinib and vemurafenib, both small molecule kinase inhibitors (SMKI) targeting mitogen-activated extracellular signal-regulated kinase (MEK) and BRAF, respectively. BRAF mutations are functionally classified as RAS-independent - either monomers (class I) or dimers (class II) - and RAS-dependent (class III). MAP2K1 mutations are functionally classified as RAF-independent, RAF-regulated, or RAF-dependent. Preclinical studies suggest class I, but not classes II-III, BRAF mutations are sensitive to RAF monomer inhibitors (dabrafenib, encorafenib, vemurafenib) while classes I-II, but not class III, BRAF mutations are sensitive to MEK inhibitors (Yaeger R, Cancer Discovery 2019). In contrast, RAF-regulated MAP2K1 mutants have variable sensitivities to allosteric MEK inhibitors (binimetinib, cobimetinib, selumetinib, trametinib) while RAF-dependent and RAF-independent MAP2K1 mutations are resistant. KRAS mutations are generally resistant to MEK inhibitors (Johnson C, Cancer Discovery 2022). Our study described the clinical efficacy of commercially available SMKIs in patients with histiocytic neoplasms harboring non-BRAFV600E mutations and compared the findings with preclinical data. Methods. We conducted a retrospective chart review of patients with histiocytic neoplasms who were treated with SMKI at Mayo Clinic. Only those who had adequate genomic testing and non-BRAFV600E mutations were included. Responses were categorized as complete (CR), partial (PR), or none (NR) based on established criteria. Results. We identified 31 non-BRAFV600E patients treated with SMKI (2 LCH; 20 ECD; 9 RDD). The median age at diagnosis was 61 years (range: 16-76) and 52% were females. The distribution of BRAF mutations was: class I (V600delinsRE [1]), class II (V495A [1], V471F [1], N486_P490del [2], GAB2-BRAF [1], UBR2-BRAF [1], RNF11-BRAF [1], UBTD2-BRAF [1]), and class III (G466E [1], D594A [1]). The only patient with class I mutation received cobimetinib and had PR. Among those with BRAF class II mutations, 2 received vemurafenib and had NR, while 9 received MEK inhibitors (binimetinib, cobimetinib, trametinib) and most responded (3 CRs, 5 PRs). The patient who had NR required dose reductions due to side effects. Both patients with class III mutation did not respond to cobimetinib. The median duration of responses was 19 months (range: 3+ to 45+) and 3 patients progressed subsequently. The distribution of MAP2K1 mutations was: RAF-independent (E102_103del [2]), RAF-regulated (I103N [1], K57T [1], Q56P [3], F53L [1], K57N [1]) and RAF-dependent (Y130C [1], D67N [1]). Both patients with RAF-independent mutations treated with cobimetinib had PRs. All patients with RAF-regulated mutations treated with allosteric MEK inhibitors responded (3 CRs, 5 PRs). Both patients with RAF-dependent mutations treated with cobimetinib responded (1 CR, 1 PR). The median duration of responses was 15 months (2 to 29+) with 3 patients progressing after treatment cessation due to intolerance. The distribution of RAS mutations was: NRAS (Q16R [1]) and KRAS (K117N [3], A146T [1], T581 [1], G13C [1], G12D [1]). Most patients treated with allosteric MEK inhibitors responded (3 CR, 4 PR, 1 NR). The median duration of response was 15 months (5 to 41) and 2 patients subsequently progressed, one of them after treatment cessation. Conclusions. Among patients with histiocytic neoplasms with non-BRAFV600E mutations receiving SMKI, our study found mixed patterns of concordance between pre-clinical predictions and clinical responses. There was concordance of efficacy in the setting of BRAF classes I-III and MAP2K1 RAF-regulated mutations. However, we found discordant findings in patients harboring RAF-dependent and RAF-independent MAP2K1 mutations as well as KRAS mutations as most responded to allosteric MEK inhibitors.
First-Line Treatment Choice and Risk of Other Malignancies in US Veterans Diagnosed with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Azevedo, Roberta S. , Gupta, Pankaj , Ma, Helen , Parikh, Sameer A. , O’Brien, Susan , Ferrajoli, Alessandra

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 5038-5038

10.1182/blood-2024-207780 Get It

Introduction: Patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) have a higher risk of developing other malignancies compared to the general population (Greene et al, J NCI 1978). Chemoimmunotherapy has previously been the mainstay of treatment and was associated with increased rates of other cancers (OC) (Thompson et al, Blood 2023). Targeted therapies such as Bruton tyrosine kinase inhibitors (BTKi) and BCL2 inhibitors were approved in the frontline setting in 2016 and 2019, respectively, and are now the standard of care for initial therapy (Shanafelt et al, NEJM 2019; Fischer et al, NEJM 2019). This study aims to compare the incidence of OC in patients with CLL/SLL treated with frontline therapies or managed with active surveillance. Methods: This is a retrospective case-control analysis of patients diagnosed with CLL/SLL during or after 2016 using the Department of US Veteran Affairs Central Cancer Registry (VACCR). Cases were patients with CLL/SLL diagnosed with incident OC, excluding nonmelanoma skin cancers. Frontline treatment with chemoimmunotherapy, monoclonal antibodies alone, or targeted therapies, such as BTKi or BCL2 inhibitor, was the exposure of interest compared to patients on active surveillance. Patients were followed until date of OC, death, or last follow up. Descriptive statistics were used to summarize continuous and categorical variables. Logistic regression was used to analyze the risk of developing OC while adjusting for potential confounders. Results: We identified 5244 patients with CLL/SLL who met inclusion criteria. Median follow up was 3.19 years (interquartile range [IQR] 1.61-5.14). The median age at diagnosis of CLL/SLL was 71.7 years (IQR 66.1-77.3) and most patients were white (78%) and male (97%). 3,460 (66%) patients were managed with active surveillance and 1,784 (34%) patients required frontline treatment: 1,318 (25%) targeted therapy, 329 (6%) chemoimmunotherapy, and 137 (3%) monoclonal antibodies alone. In patients treated with targeted therapies, patients were treated with ibrutinib (776, 59%), acalabrutinib (246, 19%), zanubrutinib (129, 10%), venetoclax (164, 12%), or combination of ibrutinib and venetoclax on a clinical trial (3, &lt;1%). 505 (10%) patients were diagnosed with OC and 4739(90%) patients did not develop OC during the follow up period after diagnosis of CLL/SLL. Types of OC observed included neoplasms of the lung (120, 24%), prostate (105, 21%), gastrointestinal tract (72, 14%), hematologic malignancies (68, 13%), melanoma (45, 9%), kidney and bladder (43, 9%), head and neck (16, 3%), and other/unknown (36, 7%). More patients with OC had a history of tobacco use compared to those diagnosed with CLL/SLL without OC (70% vs 54%, p&lt;0.0001). Fewer patients with OC had a history of alcohol use (60% vs 67%, p&lt;0.0001). In a logistic regression analysis adjusted for age at diagnosis of CLL, race, and tobacco and alcohol use patients treated with chemoimmunotherapy had a higher risk of OC compared to those on observation (OR 2.4, 95% CI: 1.7-3.3, p&lt;0.0001) whereas patients treated with targeted therapies or monoclonal antibodies alone did not have a higher risk of OC (OR 1.1, 95% CI 0.9-1.4 and OR 1.4, 95% CI 0.8-2.6, respectively) compared to the patients on active surveillance. A higher proportion of patients with OC were deceased compared to those without OC, 219/505 (43%) vs 1261/4739 (27%), respectively (p&lt;0.0001) at cutoff date. Similar analyses of occurrence of OC in patients followed at tertiary centers including MD Anderson in Houston, Texas and Mayo Clinic in Rochester, Minnesota are ongoing and will be presented at the meeting. Conclusion: Initial treatment with targeted therapies or monoclonal antibodies alone was not associated with an increased risk of OC in US veterans diagnosed with CLL/SLL during and after 2016. However, initial treatment with chemoimmunotherapy was associated with a significant increase of OC compared to patients with CLL/SLL managed with active surveillance.
Real-World Clinical Outcomes in Patients Initiating Covalent Btki (cBTKi) with and without Incident Cardiovascular Adverse Events By Line of Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Nigris, Enrico De, Leng, Siyang , Farooqui, Mohammed Z.H. , Yapici, Halit O. , Weimer, Ian , Jiao, Weiqi , Zhang, Xuan , Lodaya, Kunal, Dingli, David , Hyatt, Hayden W. , Obeng‐Kusi, Mavis

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3722-3722

10.1182/blood-2024-198469 Get It

Background: CLL is one of the most common types of leukemia in the United States, with an estimated 20,700 new cases in 2024. Although cBTKis have become the standard of care for CLL/SLL in treatment-naïve and relapsed/refractory patients, cardiovascular (CV) toxicity is a known side effect. Further, clinical outcomes often worsen as patients progress beyond 1st-line therapy (1L), and the frequency of CV adverse events (CVAEs) may increase with age and as patients progress to 2nd-line or later therapies (2L+). This research evaluated the real-world incidence of CVAEs and clinical outcomes in patients who initiated cBTKi between 2020 and 2023. Methods: Adult patients diagnosed with CLL/SLL who initiated cBTKi treatment (index date) between 2020-2023 in the United States were identified using claims data from Optum's de-identified Clinformatics® Data Mart Database and followed up to 36 months post-index. Cohorts were assessed as those initiating 1L or 2L+, reflecting treatment-naïve and relapsed/refractory patients. Results were presented for patients with an incident CVAE (not present pre-index) and those without. Demographics, incident CVAEs, overall survival (OS) and proportion of patients who discontinued index cBTKi therapy, initiated next treatment or experienced death (NT+D) were assessed. Time to CV event (TTCE) for ibrutinib and acalabrutinib were determined using a Kaplan-Meier (KM) model and Log rank test. Results: Overall, 2,163 eligible patients were identified with a mean ± SD age of 73.8 ± 9.2 years, and 40.6% were female. Of these, 1,958 (90.5%) were included in the 1L cohort and 205 (9.5%) in the 2L+ cohort; 619 (31.6%) and 63 (30.7%) patients had CVAEs, respectively. The mean ± SD [median] observation period was 1.6 ± 0.9 [2.0] years in 1L and 1.5 ± 1.0 [1.0] years in 2L+. The most common cBTKi (in 1L and 2L+) at index were ibrutinib (55.5% and 55.6%), followed by acalabrutinib (40.3% and 38.5%), and zanubrutinib (4.1% and 5.9%). At 12-months post-index, the proportion of 1L patients with and without CVAEs who discontinued treatment was 44.9% and 41.6%, rising to 65.6% and 59.0% by 36-months post-index, respectively. For those in 2L+, 50.8% and 40.8% of those with and without CVAEs discontinued treatment by 12-months; 68.3% and 55.6% discontinued by 36-months. Among those with and without CVAEs, NT+D in 1L patients was 35.9% and 22.5% within 12-months post-index and 56.9% and 32.8% by 36-months. In the 2L+ cohort, 46.0% and 31.7% experienced NT+D by 12-months, rising to 63.5% and 41.5% by 36-months. OS in 1L patients was 84.7% and 93.1% in those with and without CVAEs at 12-months and 69.1% and 88.0% at 36-months. For 2L+ patients, OS was 71.4% and 88.0% at 12-months and decreased to 54.0% and 80.3% at 36-months, among those with and without CVAEs, respectively. The most common incident CVAEs following cBTKi initiation in the 1L and 2L+ cohorts were hypertension (31.2% and 21.7%), heart failure (14.6% and 17.7%), atrial fibrillation (13.9% and 18.4%), atrial flutter (13.3% and 16.9%), and ventricular arrythmias (13.0% and 14.5%). The occurrence of incident CVAEs between 1L patients who received acalabrutinib and ibrutinib was 3.4% and 13.2% for atrial fibrillation, 2.7% and 12.7% for atrial flutter, 9.3% and 31.0% for hypertension, and 6.8% and 11.7% for ventricular arrythmias. For 2L+, the proportion experiencing CVAEs with index acalabrutinib or ibrutinib were 8.6% and 14.8% for atrial fibrillation, 7.6% and 14.8% for atrial flutter, 10.5% and 25.0% for hypertension, and 10.1% and 8.8% for ventricular arrythmias. Among acalabrutinib and ibrutinib patients, KM estimates (medians not reached) in 1L showed that 84% and 72% of patients would not experience a CVAE by 12 months, with 57% and 52% not experiencing a CVAE at 36-months (p&lt;0.001); 2L+ KM estimate rates were 77% and 73% at 12-months and 64% and 60% at 36-months (p=0.28). Mean TTCE for acalabrutinib and ibrutinib in 1L was 2.2 and 1.9 years with 1.6 and 1.2 years in 2L+. Summary/Conclusion: Utilizing real-world evidence from patients with CLL/SLL receiving cBTKIs, this study highlights the CV disease burden among patients who incur new CV events in 1L or later lines of therapy. This research underscores the need for innovative therapies with improved efficacy and CV safety profiles that delay progression to later lines of therapy, as well as careful CV monitoring to allow for early management and improved outcomes.